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Abstract
Purpose: Abiraterone may suppress androgens that stimulate
breast cancer growth. We conducted a biomarker analysis of
circulating tumor cells (CTCs), formalin-ﬁxed parafﬁn-embedded
tissues (FFPETs), and serum samples frompostmenopausal estro-
gen receptor (ER)þ breast cancer patients to identify subgroups
with differential abiraterone sensitivity.
Methods: Patients (randomized 1:1:1) were treated with
1,000 mg/d abiraterone acetate þ 5 mg/d prednisone (AA),
AA þ 25 mg/d exemestane (AAE), or exemestane. The biomark-
er population included treated patients (n ¼ 293). The CTC
population included patients with3 baseline CTCs (n¼ 104).
Biomarker [e.g., androgen receptor (AR), ER, Ki-67, CYP17]
expression was evaluated. Cox regression stratiﬁed by prior
therapies in the metastatic setting (0/1 vs. 2) and setting of
letrozole/anastrozole (adjuvant vs. metastatic) was used to
assess biomarker associations with progression-free survival
(PFS).
Results: Serumtestosteroneandestrogen levelswere loweredand
progesterone increased with AA. Baseline AR or ER expression was
not associated with PFS in CTCs or FFPETs for AAE versus exemes-
tane,butdualpositivityofARandERexpressionwasassociatedwith
improved PFS [HR, 0.41; 95% conﬁdence interval (CI), 0.16–1.07;
P ¼ 0.070]. For AR expression in FFPETs obtained <1 year prior to
ﬁrst dose (n ¼ 67), a trend for improved PFS was noted for AAE
versus exemestane (HR, 0.56; 95% CI, 0.24–1.33; P ¼ 0.19).
Conclusions: An AA pharmacodynamic effect was shown by
decreased serum androgen and estrogen levels and increased
progesterone. AR and ER dual expression in CTCs and newly
obtained FFPETs may predict AA sensitivity. Clin Cancer Res; 22(24);
6002–9. 2016 AACR.
Introduction
Elucidating the role of androgens in estrogen receptor (ER)þ
metastatic breast cancer has recently been a subject of interest as
androgenic signaling is predicted to be a potential mechanism of
therapeutic resistance to antiestrogenic therapy (1–3). Androgens
are themost prominent sex hormone inwomen aftermenopause,
which may allow for androgen aromatization to estradiol and
breast cancer progression through androgen receptor (AR) stim-
ulation in a low-estrogenic environment (4). More than 60% of
breast cancers express AR and androgen-regulated proteins, indi-
cating potential androgen responsiveness (4, 5). Furthermore,
exogenous AR overexpression renders tamoxifen-sensitive ERþ
breast cancer cell lines resistant to tamoxifen, providing addition-
al evidence for AR as a target for therapeutic augmentation of
combination endocrine therapies in breast cancer (6).
As such, certain subsets of breast cancers may then be sensitive
to antiandrogen strategies and thus may derive clinical beneﬁt
from the androgen biosynthesis inhibitor abiraterone acetate
(AA),whichhasproved tobe effective inhormone-drivenprostate
cancer (7, 8). In an early-phase, nonrandomized trial of post-
menopausal ERþ patients with advanced breast cancer progres-
sing on 2 lines of endocrine therapy, AA treatment was associ-
ated with a reduction in serum androgens and estrogens (9); one
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patient had a conﬁrmed partial response lasting 13.8months, and
22% of patients had clinical beneﬁt for 24 weeks, providing
preliminary evidence of efﬁcacy of AA in advanced breast cancer
(9). However, in the randomized phase II study BCA2001 of ERþ
HER2 postmenopausal breast cancer patients who had pro-
gressed on nonsteroidal aromatase inhibitors (NSAI), no
improvement in the primary endpoint of progression-free surviv-
al (PFS) was observed with the addition of AA to exemestane
compared with exemestane alone [4.5 vs. 3.7 months, hazard
ratio (HR) 95% conﬁdence interval (CI) ¼ 0.96 (0.70–1.32);
P ¼ 0.79; ref. 10]. As androgen blockage remains a potential
therapeutic strategy for a clinically deﬁned subset of breast cancer
patients, further understanding of the pathogenesis of breast
cancer and mechanism of action of AA in breast cancer patients
would provide the framework for individualization of this drug
therapy.
We hypothesized that breast cancer tumors with active AR
signaling or residual ER activity after progression on an aromatase
inhibitor may derive clinical beneﬁt from AA. We therefore con-
ducted a biomarker analysis of study BCA2001 to analyze serum
steroid concentrations for changes from baseline and to poten-
tially identify subgroups with AA sensitivity or resistance using
tumor biomarkers in archival formalin-ﬁxed parafﬁn-embedded
tissues (FFPET) and circulating tumor cell (CTC) samples.We also
investigated the congruency of biomarkers in these two sample
types.
Patients and Methods
Study design and treatments
BCA2001 is a randomized, open-label, multicenter phase II
study of 1,000 mg AA plus 5 mg prednisone daily (hereafter
referred to as AA) versus AA plus prednisone with 25 mg exemes-
tane (AAE) daily versus the control arm (25mg exemestane alone
daily [E]) in patients with postmenopausal ERþ HER2 breast
cancer after receiving NSAIs (10). Patients could have had no
more than two prior systemic treatments in themetastatic setting,
of which one could be chemotherapy, and an EasternCooperative
Oncology Group performance status (ECOG PS) score of 1.
Patients were stratiﬁed by the number of prior therapies in the
metastatic setting (0 or 1 vs. 2) and the setting of prior letrozole or
anastrozole treatment (adjuvant vs. metastatic).
The review boards at all participating institutions approved the
study, which was conducted according to the Declaration of
Helsinki; all patients provided written, informed consent to
participate in the study.
Biomarker analysis
Several biomarkers associated with themechanism of action of
the study drugs, or with the development and progression of
breast cancer, were evaluated from archival FFPETs, CTCs, and
serum samples (Supplementary Table S1).
Immunohistochemistry and FISH analysis of archival FFPETs
Immunohistochemistry (IHC) and FISH analysis of archival
FFPETswere conducted at Phenopath Labs. IHC analysis was used
to assess the baseline expression of ER (Thermoﬁsher #RM-9101-
S; SP1 clone), progesterone receptor (PR; Dako #M3569; PgR636
clone), HER2 (Thermo-Fisher #RM-9103-S, SP3 clone), cyto-
chrome P450 17A1 (CYP17A1; Abcam#Ab80206), aromatase/
cytochrome P450 19A1 (CYP19A1; Novus Biological
#AP00001PU-N), Ki-67 (Dako, #M7240; MIB-1 clone), and AR
(Dako, #M3562, Clone AR441), in FFPETs. The percentage of
positively staining cells, intensity of staining (weak, moderate,
strong), and presence of positive internal controls were evaluated.
ER and PR positivity was accessed by scoring according to the
American Society of Clinical Oncology College of American
Pathologists (ASCO/CAP) guidelines (11). Expression of ER and
PR at any intensity greater than 1% of tumor cells was considered
positive. ExpressionofHER2was accessedwith amodiﬁedASCO/
CAP guideline (12). For HER2, CYP17, and CYP19, the cutoff
point for positive expression was also 1% of tumor cells. To
determine Ki-67 positivity, nuclear staining was scored as a
percentage of cells positive relative to nonreactive cells within
the target. Expression of Ki-67 and AR at any intensity greater than
10% of tumor cells was considered positive.
IHC and FISH analysis of CTCs
Blood samples (40 mL) were taken on day 1 of cycles 1 and 2
and at the end of treatment (EOT) or disease progression, and
shipped to the Janssen Diagnostics CRS lab for CTC enumeration
(CellSearch; Janssen Diagnostics) andmolecular characterization
as previously described (13, 14). A three-CTC threshold is used for
CTCmolecular marker evaluations, whereas a ﬁve-CTC threshold
separates favorable and unfavorable prognosis. Only samples
with three or more evaluable CTCs were included to ensure
conﬁdence of positive versus negative biomarker determinations.
Biomarkers tested in CTCs included expression of AR (Cell Sig-
naling Technology #8428,D6F11 clone), ER (JanssenDiagnostics
ER-119.3), and Ki-67 (BD Pharmingen #556027, clone B56) by
immunoﬂuorescence. For ER and Ki-67 expression analysis, the
percentage of positive cells was determined by nuclear ﬂuores-
cence in the phycoerythrin channel, with >80% positive MCF-7
cells spiked into normal donor blood as a positive control. For AR
expression analysis, LNCaP cells were spiked into normal donor
blood as a positive control and PC-3 cells as a negative control.
The cutoff points for positive expression of ER, Ki-67, andARwere
the same as noted above.
Translational Relevance
A subset of nonsteroidal aromatase inhibitor–resistant,
estrogen receptor–positive breast cancers may be sensitive to
antiandrogen drugs and thus may derive clinical beneﬁt from
the androgen biosynthesis inhibitor abiraterone acetate (AA).
A biomarker analysis can be useful to identify predictive
biomarkers for AA sensitivity or resistance. The effect of AA
administration on serum testosterone has been well charac-
terized but not the effect on a panel of other serum endocrine
biomarkers. In our biomarker analysis, a positive pharmaco-
dynamic effect of AA was shown by the decrease in serum
estrogens and androgen and potentially by the increase in
progesterone in most AA-treated patients. Despite association
trends of certain biomarkers with progression-free survival
(PFS), none of the biomarkers, either as single markers or in
combination, could identify a subpopulation of patients with
signiﬁcant added clinical beneﬁt from AA. Importantly, no
association between the elevated serum progesterone induced
by AA administration and PFS was observed.
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A four-color FISH assaywas developed for use on enrichedCTC
to simultaneously detect ampliﬁcation of HER2 and AR genes as
well as aneusomy of chromosomes X and 17. The assay uses
control probes on the centromere of chromosome 17 (Kreatech
SE17, Leica Biosystems) and the X chromosome (Kreatech SE-X,
Leica Biosystems) to determine the overall ploidy level of the cell
assessed. The Clone IDs for bacterial artiﬁcial chromosomes
(BAC) utilized as probes to evaluate HER2 were RP11-62N23,
RP11-94L15, and RP11-387H17. BAC clones evaluated for AR
were RP11-383C12, RP11-479J1, and RP11-963N10. Samples
were considered positive for FISH, positive for HER2 and AR gene
ampliﬁcation if three CTCs were found to contain ﬁve or more
copies of the target gene.
Evaluation of serum hormone concentrations
Blood samples (15 mL) for assessment of endocrine biomar-
kers were taken day 1 of cycles 1 to 3 and every three cycles
thereafter (e.g., day 1 cycle 6; day 1 cycle 9), and at EOT or disease
progression. Analysis of androgen and estrogen concentrations
was conducted according to standard operating procedures (Cov-
ance Central Laboratory Services, Indianapolis, Indiana; and
Geneva, Switzerland). Samples were analyzed for testosterone,
estradiol, and estrone by liquid chromatography–mass spectrom-
etry using an ABI Sciex QTRAP 5500 system (Applied Biosystems/
MDS Analytical Technologies). Progesterone serum concentra-
tions were determined using the Beckman Coulter Access Proges-
terone assay (Beckman Coulter Inc.) and the Dxi 800 instrument.
Progesterone concentrations were only determined for a subset of
patients, because the serumprogesterone analysis was added after
enrollment was initiated.
Statistical analysis
Baseline demographics and disease characteristics were
compared in the biomarker or CTC populations versus the
intent-to-treat (ITT) population using ANOVA and c2 tests.
Biomarkers were summarized in each of the three arms or com-
binations of the three arms by calculating the mean, standard
deviation,median, range, andnumber of sampleswith expression
for continuous variables, and the frequency of expression of
categorical biomarkers (N and %) for categorical variables.
For categorical variables, statistical comparisons were per-
formed for treatment effect (AA vs. E, AAE vs. E, or AA and AAE
vs. E) in biomarker-positive/negative subgroups or for biomarker
effect (biomarker-positive vs. -negative) in treatment arms and
overall population to identify patient subpopulations with better
PFS. Composite biomarkers were generated by combining levels
of biomarker pairs. For this composite biomarker, each individual
biomarker was dichotomized to deﬁne biomarker-positive and
-negative patient subpopulations using biomarker-speciﬁc
thresholds (e.g., AR 10%, ER 1%) or medians for endocrine
biomarkers. The composite biomarker was deﬁned by evaluating
individual biomarkers concurrently, resulting in four subpopula-
tions (i.e., ARþ and ERþ, ARþ and ER, AR and ERþ, AR and
ER). Association between biomarker expression and time to
event was represented by reporting the P value and hazard ratio
with 95% CI and the median time to event with 95% CI from
Kaplan–Meier analysis. A Cox proportional-hazards regression
analysis of PFS was performed to evaluate the treatment effect
(AA vs. E, AAE vs. E) in biomarker-positive and -negative sub-
groups, stratiﬁed according to number of prior therapies in the
metastatic setting (0 or 1 vs. 2), and setting of prior letrozole or
anastrozole treatment (adjuvant vs. metastatic).
For serum endocrine markers, treatment effects were summa-
rized by the mean, standard deviation, median, and range of
expression levels, along with the change from baseline and
percentage change from baseline. Longitudinal analysis was used
to evaluate the effect of treatment on serum endocrine marker
levels versus baseline within treatment arms. The change in serum
endocrinemarker levelswas evaluated using a linearmixed-effects
Patients randomized to treatment (N = 297)
1:1:1 ratio (enrollment to AA discontinued early)
ITT population (n = 297)
(All patients randomly assigned)
Did not receive study drug
AA (n = 2)
AAE  (n = 2)
E
(n = 102)
AA
(n = 89)
AAE
(n = 106)
CTC biomarker population (n = 104)
(All treated patients with ≥ 3 CTCs
at baseline)
E
(n = 37)
AA
(n = 31)
AAE
(n = 36)
Biomarker population (n = 293)
(All patients treated on the study)
E
(n = 102)
AA
(n = 87)
AAE
(n = 104)
Figure 1.
CONSORT diagram. FFPETs were
collected from all patients. E,
exemestane; AAE, abiraerone acetate
and exemestane; ITT, intent-to-treat
population.
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Figure 2.
Longitudinal analysis of serum endocrine markers.A, Testosterone. B, Progesterone. C, Estradiol. D, Estrone. E, exemestane; AAE, AA and exemestane; C1D1, cycle 1
day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 day 1; C6D1, cycle 6 day 1; C9D1, cycle 9 day 1; EOT, end of treatment.
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model with ﬁxed effects for visit, treatment and the visit treatment
interaction, and a randomeffect for patients. For CTCbiomarkers,
treatment effectswere summarizedby the count or average of total
CTCs, count and percentage of biomarker-positive CTCs, change
of total CTCs and biomarker-positive CTCs from baseline, and
change in percentage of biomarker-positive CTCs.
CTC conversion rates were enumerated by tabulating the num-
ber of patients in each treatment arm with 5 CTCs at baseline
and <5 CTCs at cycle 2 or EOT instead of the3 CTCs cutoff used
to select patients for CTC molecular analysis. Additionally, the
CTC conversion rates at cycle 2 and EOT were compared across
treatment arms in biomarker (CTC or IHC AR expression) -pos-
itive versus -negative populations. Fisher exact test was used to test
the associations between treatment arms and CTC conversion
rate. Expression using IHC and CTC biomarkers at baseline was
compared.
Results
Patient demographics
Two hundred ninety-seven patients were enrolled in the
BCA2001 trial starting inAugust 2011andwere randomlyassigned
1:1:1 to the E (n¼ 102), AA (n¼ 89), or AAE (n¼ 106) treatment
arms (Fig. 1). The primary PFS results have been presented previ-
ously (15). Of the 293 patients (E, n ¼ 102; AA, n ¼ 87; AAE,
n ¼ 104) who received treatment and comprised the biomarker
population, 104 (E, n ¼ 37; AA, n ¼ 31; AAE, n ¼ 36) were
evaluable at baseline and were included in the CTC biomarker
population. The remainingpatientswere deemedunevaluable and
were excluded from the analysis due to inadequate levels of CTCs,
provision of samples outside the required timeframe for CTC
testing, unsatisfactory samples due to insufﬁcient blood volume,
or unreliable samples due to failure of baseline CTC testing.
The CTC biomarker populations were comparable to the ITT
population with regard to patient demographics and baseline
disease characteristics (10). The median age was 62 (39–81) and
63 (37–87) years in the CTC biomarker population and ITT
population, respectively. Visceral metastatic disease was observed
in 40% versus 46%of the patients. Altogether, 23% versus 28%of
patients had two prior treatments in the metastatic setting with
66% comparedwith 64%of patients receiving a prior NSAI in this
setting.
Biomarker analysis
A longitudinal analysis of endocrine serum markers compared
within arms at several time points is presented in Fig. 2. As
expected, serum testosterone was signiﬁcantly decreased over
time (P < 0.0001) in the AA and AAE treatment arms (93.7%
and93.1% change, respectively) but not in the E arm (15.6%;
P ¼ 0.29) by C2D1. AA-induced suppression of testosterone was
persistent in both arms through EOT (76.3% and 76.2%,
respectively). Estradiol and estrone levels were decreased in these
AA treatment arms. No statistically signiﬁcant difference in the
reductionof estradiol or estronewas observedbetween arms (data
not shown).
A signiﬁcant increase in serum progesterone concentrations
was noted in AA-treated patients (2666.4% and 1689.0% in
AA and AAE arms, respectively; P < 0.0001) compared with E
alone (56.6%; P > 0.99) by C2D1 (Fig. 2). In a separate
analysis, the AA-induced increase in progesterone was not
associated with PFS based on stratiﬁed Cox proportional-
hazards regression analysis (data not shown). Upon further
analysis of median PFS in the patients with a decrease in
progesterone at C2D1 versus all patients, there was no asso-
ciation with shorter PFS in patients with a decrease in
progesterone (data not shown).
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Figure 3.
Comparison of associations of the positive baseline expression of AR (10%)
with PFS. A, CTCs. B, FFPETs by immunohistochemistry. C, FFPETs collected <1
year before ﬁrst dose. Positive (10%). E, exemestane; AAE, AA and
exemestane.
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Baseline FFPETs and CTCs were evaluated for AR and ER as
single and combinedbiomarkers to assess the impact ofAAonPFS
for ERþHER2 disease. There was a positive association with PFS
for the combination of AR and ER expression in CTCs in favor of
AAE versus E (HR, 0.41; 95% CI, 0.16–1.07; P ¼ 0.070; Supple-
mentary Table S2). Evaluated as single biomarkers, a positive
expression of AR (Fig. 3A and B) or ER in baseline CTCs or in the
FFPETswas not associatedwith an improvement inPFSwithAAor
AAE versus E. No association between negative AR expression and
improved PFS in the three arms was also noted (Supplementary
Fig. S1A and B). Loss of ER or AR expression in CTCs was also not
associated with a difference in PFS with AA or AAE versus E.
For patients with FFPETs obtained <1 year prior to ﬁrst dose
(n ¼ 67; Fig. 3C), positive AR expression was associated with an
improvement in PFS for AAE versus E (HR, 0.56; 95% CI, 0.24–
1.33; P ¼ 0.19). Negative AR expression in these same recent
FFPETs was not associated with an improvement in PFS for AAE
versus E (Supplementary Fig. S1C). For completeness, we evalu-
ated the sensitivity of the results to the threshold used to dichot-
omize low versus high expression. We found that the results were
invariant to the speciﬁc threshold chosen (data not shown).
Additional biomarkers were evaluated for a potential asso-
ciation with PFS (Supplementary Table S2). A longer median
PFS was observed for positive Ki-67 expression in CTC
samples (deﬁned as 10% staining) in AAE-treated patients
(3.7 months; HR, 0.26; 95% CI, 0.11–0.64; P ¼ 0.003), and
when AA and AAE arms were combined (3.5 months; HR, 0.36;
95% CI, 0.17–0.76; P ¼ 0.007) compared with the E arm
(1.9 months). Conversely, a statistically signiﬁcant improve-
ment in PFS with AAE was not noted for positive Ki-67 expres-
sion (10%) in FFPETs obtained at diagnosis. Patients with low
serum estrone levels at baseline in the AAE and combined AA
and AAE groups also showed an improvement in PFS over
patients in the E arm (4.2 months; HR, 0.67; 95% CI, 0.43–
1.04; P ¼ 0.07 vs. 3.7 months, HR, 0.71; 95% CI, 0.48–1.05;
P ¼ 0.09 vs. 1.9 months, respectively). No improvement in PFS
was associated with expression of CYP17 or CYP19 in FFPETs.
With regard to the post-baseline CTC analysis (Table 1), all
patients' CTCs were negative for ER ampliﬁcation by FISH at
baseline and post-baseline. There were signiﬁcantly lower CTC
counts in the AA arms compared with E alone at cycle 2 day 1
(P¼ 0.0075) but not at EOT (P¼ 0.95). No difference in CTC AR
expression or CTC ER expression post-baseline was observed
between treatment groups.
Discordance in CTC and FFPET expression of biomarkers was
observed. In total, 11 of 58 (19%), 25 of 77 (33%), and 7 of
44 patients (16%) whose breast cancers were positive for expres-
sion of AR, ER, andKi-67, respectively, in FFPETswere negative on
CTC analysis (Table 2). An observed discordance occurred in
similar frequencies for all three of these biomarkers.
Table 1. Post-baseline analysis of treatment effect on CTC markers
Biomarker Visit Treatment N Mean Differential estimate (95% CI) P value
CTC counts C1D1 E 36 45.89 — —
AA 31 25.10 — —
AAE 34 68.24 — —
AA and AAE 65 47.66 — —
C2D1 E 25 81.89 — —
AA 28 27.25 –1.10 (–1.92 to –0.29) 0.0075
AAE 31 24.35 –1.21 (–2.02 to –0.43) 0.0026
AA and AAE 59 25.73 –1.16 (–1.89 to –0.48) 0.0012
EOT E 20 48.68 — —
AA 17 47.18 –0.03 (–0.92 to 0.88) 0.95
AAE 20 77.66 0.47 (–0.39 to 1.33) 0.28
AA and AAE 37 63.65 0.27 (–0.51 to 1.00) 0.48
CTC AR C1D1 E 25 43.96 — —
AA 25 45.20 — —
AAE 30 35.70 — —
AA and AAE 55 40.02 — —
C2D1 E 19 51.74 — —
AA 18 45.50 –6.24 (–24.14 to 11.67) 0.49
AAE 25 41.48 –10.26 (–26.83 to 6.31) 0.22
AA and AAE 43 43.16 –8.57 (–23.57 to 6.42) 0.26
EOT E 14 41.07 – –
AA 15 49.87 8.80 (–12.17 to 29.76) 0.41
AAE 18 28.39 –12.68 (–32.78 to 7.42) 0.21
AA and AAE 33 38.15 –2.92 (–20.91 to 15.07) 0.75
CTC ER C1D1 E 25 27.84 — —
AA 25 27.64 — —
AAE 27 25.04 — —
AA and AAE 52 26.29 —
C2D1 E 12 19.75 — —
AA 12 29.08 9.33 (–9.31 to 27.98) 0.32
AAE 11 26.09 6.34 (–12.72 to 25.40) 0.51
AA and AAE 23 27.65 7.90 (–8.36 to 24.16) 0.33
EOT E 13 28.08 — —
AA 13 37.54 9.46 (–13.70 to 32.62) 0.42
AAE 18 28.17 0.09 (–21.40 to 21.58) 0.99
AA and AAE 31 32.10 4.02 (–15.49 to 23.53) 0.68
Abbreviations: AR, androgen receptor; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; EOT, end of treatment.
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Loss of ER expression may occur over time such that FFPETs
initially characterized as ERþmay be ER at the time of treatment
for metastatic disease. Our analysis demonstrated that 33% and
16% of initially positive breast cancer had lost ER or AR, respec-
tively, in their CTCs. We evaluated whether loss of ER or AR is
associated with worse outcomes by evaluating PFS differences
between biomarker-positive and -negative patients for each of the
AA treatment arms versus E. No signiﬁcant differences in out-
comes were observed (data not shown).
Discussion
This is the ﬁrst report of a biomarker assessment of AA-treated
postmenopausal ERþ advanced breast cancer patients based on
serum endocrine analysis, FFPETs, and CTCs. The goal of this
study was to assess baseline biomarkers that were highly associ-
ated with treatment response for stratiﬁcation strategies and to
track molecular and endocrine changes throughout the course of
treatment. If a positive marker could be identiﬁed, uncertainty in
predicting clinical beneﬁt fromcurrent therapeutic options,which
often leads to ineffective treatment of disease, can be avoided.
Biomarker-driven therapeutic decision-making can potentially
offer valuable information on surrogate markers for disease
progression and treatment in the clinical setting.
A positive pharmacodynamic effect of AA was shown by the
decrease in serum androgen levels as well as estrogen levels
(Fig. 2). Because CYP17 is upstream from aromatase in the steroid
synthesis pathway, theoretically, AA should inhibit production of
estrogens. Data from this study showed that AA decreased circu-
lating estradiol and estrone to a level comparable with E alone.
A trend of sensitivity was observed in certain subsets of bio-
markers analyzed in this study, but the improvement in terms of
longer PFSwas generally not clinically signiﬁcant. BaselineARand
ER expression in CTCs or FFPETs was not observed to be asso-
ciated with improved PFS with AA or AAE versus E, though
baseline AR and ER dual expression in CTCs may have an
association with improved PFS (Supplementary Table S2).
We hypothesized that loss of ER expression in CTCs might
predict resistance to AA because of insensitivity of ER tumors to
hormonal therapy.However, even though loss of ERwas observed
in a subset of CTCs, it was not predictive of worse PFS with AA.
Potential reasons for this outcome include discordance between
diagnostic and CTC samples, or cross-talk between AR and ER
signaling.
Some limitations to analysis of CTC may have affected inter-
pretations made from this study. One limitation is the small
number of patients who have sufﬁcient numbers of CTCs for
analysis. In this study, only 39% (104/266) of the treated patients
who provided CTCs had three or more CTCs at baseline for
inclusion in the population for biomarker analysis. We found
that there was 81% concordance between AR positivity in FFPE
versus CTC, whereas 32.5% of CTC samples lost ER expression.
Loss of ER expression in CTCs can be attributed to a number of
potential factors, including repopulation of tumor cells in
response to various treatments after FFPETs were taken, intra-
and inter-lesion heterogeneity of ER expression, lack of sufﬁcient
evaluable CTCs, and differences in IHC and CTC staining meth-
ods. Well-controlled future studies are needed to determine the
exact cause of the discordance of ER status.
Positive AR expression in FFPETs obtained <1 year prior to the
ﬁrst dose was associatedwith improved PFS in the AAE arm versus
E (Fig. 3C), while AR expression assessed in all the archival FFPETs
[some as old as 25.67 (0–25.67) years] was not. Samples collected
more recently could have had a greater correlation of PFS with AA
treatment due to antigen preservation, more recent samples being
more representative of current tumor status, and/or differences in
sample quality (signal may not be stable in older samples). In
addition, a higher proportion of metastasis in recently collected
samples compared with older samples (OR ¼ 3.26, P ¼ 0.005)
could have affected these ﬁndings.
The methods used in these analyses also did not allow for
multiplex testing,whichwouldhave enabledmultiple biomarkers
tobemeasured simultaneously (16). Thismay affect data accuracy
andappearanceofdiscordance, as only a few individualmolecular
markers provide adequate sensitivity for CTC detection. Further-
more,multiple individual assays require sufﬁcientCTC sample for
each analysis, which limits the biomarker population to those
patients who have higher levels of CTCs. Because of this, it is
possible that patients weremisclassiﬁed as biomarker-negative by
CTC testing based on deﬁned cutoff points because there were not
enough CTCs detected and available for the determination of
status of individual CTCs, contributing to discordance.
The lack of an observed positive association between AR
expression and improved PFS with AAmay be due to AA-induced
progesterone production (Fig. 2). Progesterone potentially acts as
an agonist that induces growth and survival of ERþ breast cancer.
Importantly, in this evaluation of the association of baseline
progesterone with PFS as continuous variable, patients with
higher baseline progesterone concentrations had shorter PFS in
all arms. The prognostic value of baseline progesterone, however,
diminished after initiation of treatment in all arms. Evaluation of
the association of elevated progesterone levels with PFS in sam-
ples on-treatment and posttreatment with AA was not feasible,
because almost all patients treated with AA had elevated serum
progesterone levels. Progesterone levels were observed to be
nominally lowered by 56.6% in the E arm at C2D1. This decrease
of progesterone, however, was not statistically signiﬁcant andwas
likely due to an outlier and not a real treatment effect.
In conclusion, our analyses show that AA treatment decreased
serum testosterone and estrogen levels but increased progesterone
concentrations in ERþ HER2 NSAI-resistant metastatic breast
cancer patients. Baseline AR and/or ER expression in CTCs or
Table 2. Discordance of CTC at baseline and FFPET at diagnosis
–CTC þCTC
AR, n (%) – by IHC 4 (23.5) 13 (76.5)
þ by IHC 11 (19.0) 47 (81.0)
ER, n (%) – by IHC — —
þ by IHC 25 (32.5) 52 (67.5)
Ki-67, n (%) – by IHC 7 (36.8) 12 (63.2)
þ by IHC 7 (15.9) 37 (84.1)
Cutoff points for positive expression: AR, 10%; ER, 1%; Ki-67, 10%.
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archival FFPETs was not associated with improved PFS for AA
treatment arms versus E. However, an analysis of recent FFPETs,
which may be more representative of the current metastatic
disease biology, suggested that AR expression predicted for
improved PFS with AA treatment, potentially due to the enrich-
ment of AR in metastatic breast cancers that had been previously
treated with a NSAI (6). Due to the small sample size, the
hypotheses generated in these exploratory analyses need to be
conﬁrmed in further studies. However, due to a lack of signiﬁcant
improvement in clinical outcomes in the primary phase II trial
(15), a phase III trial of the combination of AA and E in this breast
cancer patient population was not pursued.
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